Neomorph raised an additional $100 million in funding to advance molecular glue programs, expanding resources for discovery and translation of degradation-oriented therapeutics. The company’s Series B round was framed as supporting platform work in molecular glues, which are small molecules that induce or stabilize protein-protein interactions to drive selective degradation or functional disruption. With the funding, Neomorph said it will press on program execution toward IND-enabling activities and clinical preparation, highlighting that investors continue to fund modality expansion beyond traditional antibodies and targeted small molecules.